Roche concerned about 'neglect' of patent rules in India, but stays committed
This article was originally published in Scrip
Executive Summary
Days after a second patent-related setback in India in recent times, Roche says that it is concerned about a "policy of neglect" for patent rules that would inhibit future research, though the Swiss firm stressed that it continues to stay "committed" to its business in India.
You may also be interested in...
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Need a specific report? 1000+ reports available
Buy Reports